Cancer Diagnostics, Inc.
Durham, NC
- UEI
- TU4VHMALAAZ3
- CAGE
- 397F1
- Primary NAICS
- 325413 In-Vitro Diagnostic Substance Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 116 Page Point Cir, Durham, NC 27703, USA
- Website
- cancerdiagnostics.com
- Founded
- 1998
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $90,000 |
| FY2025 | $0 |
| FY2024 | $0 |
| FY2023 | $102,435 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $90,000 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Biocare Medical LLC | Pacheco, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Newcomer Supply, Inc. | Waunakee, WI | 423450 Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers |
| Agilent Technologies Inc. | Carpinteria, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Sakura Finetek U.s.a., Inc. | Torrance, CA | 423450 Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers |
| Invivoscribe, Inc. | San Diego, CA | 325413 In-Vitro Diagnostic Substance Manufacturing |
About the company
Cancer Diagnostics, Inc., a for-profit manufacturer of anatomic pathology and histology products based in Durham, North Carolina, supplies specialized laboratory equipment and reagents to federal health agencies exclusively as a prime contractor operating in full-and-open competition with no set-aside designations.
The vendor's federal footprint centers on a narrow customer base. The Defense Health Agency accounts for 6 awards totaling $8.6 million in combined potential value — roughly 99% of the vendor's recent federal dollars — with the remaining activity split among the National Cancer Institute ($90 thousand), the Veterans Health Administration (two separate regional networks accounting for $19 thousand combined), and the National Institute of Allergy and Infectious Diseases ($5 thousand). The Defense Health Agency relationship runs primarily through a single BPA (HT001418A0019) with five task orders valued at $558 thousand combined. Cancer Diagnostics' work under DHA supports the anatomic pathology lab at Walter Reed Medical Center, supplying Auto Frost IHC microscope slides, tissue marking dyes, and related gross specimen processing materials. Recent representative awards include a $90 thousand firm-fixed-price purchase order from the National Cancer Institute for a TintoStainer Plus Automated IHC Stainer with 30-slide capacity (September 2026, performance through Durham), a $102.4 thousand DHA BPA call for tissue marking dye and microscope slides (January 2023, delivery through September 2023), and a $101 thousand DHA BPA call for Auto Frost IHC slides and specimen processing materials supporting Walter Reed (December 2021 through December 2022).
Activity is sparse and episodic — one award per year in 2019, 2020, and 2021, then no recorded federal awards in 2022 and 2024, followed by one award each in 2023 and 2026. Combined potential value across 43 historical awards stands at $8.7 million, with only $679 thousand obligated to date (8% of potential). One award ($90 thousand NCI purchase order) reaches ultimate completion within the next twenty-four months and faces potential recompete. Cancer Diagnostics operates as a 100% prime vendor with no subcontract footprint.
SBA capabilities narrative
Cancer Diagnostics Inc developed the first commercially available 7-dye color kit for marking tissue margins, Cancer Diagnostics Inc's Tissue Marking Dyes; and today offers one of the industry's largest portfolio of anatomical pathology products to over 3,500 laboratories worldwide with shipping locations throughout the United States. Our passion is improving the customer experience with better products and service. Reliable products, easy ordering, on-time deliveries, value and guaranteed satisfaction. Visit us at http://cancerdiagnostics.com to view our products and catalogs.
Quick answers
Is Cancer Diagnostics, Inc. registered in SAM.gov?
Yes. Cancer Diagnostics, Inc.'s SAM.gov registration is active through January 22, 2027.
How much has Cancer Diagnostics, Inc. received in federal contracts?
Federal contracts obligated $192,435 to Cancer Diagnostics, Inc. in fiscal years 2023 through 2027.
What is Cancer Diagnostics, Inc.'s most recent federal award?
Cancer Diagnostics, Inc.'s most recent federal contract award is NCI: tintostainer plus automated IHC stainer, 30 slide capacity (75N98026P01420), from Office of Logisitics and Acquisition Operations (NIH), on September 18, 2026.
On GovTribe
See Cancer Diagnostics, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors